Stockreport

Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy

AIMMUNE THERAPEUTICS  (AIMT) 
Last aimmune therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.aimmune.com/corporate-profile
PDF BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, [Read more]